

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the month of May 2024**

Commission File Number: **001-39777**

**Nanobiotix S.A.**

(Translation of registrant's name into English)

**60 Rue de Wattignies 75012 Paris, France**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

---

On May 15, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[\(c\) Exhibit 99.1. Press release dated May 15, 2024](#)

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Nanobiotix S.A.  
(Registrant)

Date: May 15, 2024

/s/ Bart Van Rhijn  
Bart Van Rhijn  
Chief Financial Officer

## NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024

Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST

PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “**Company**”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets open.

This release will be followed by a conference call and webcast on May 22, 2024 at 8:00 am EDT / 2:00 pm CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s first quarter of 2024 results and provide an update on business activities before taking questions from participants.

Details for the call are as follows:

Audio-only dial-in link: [click here](#)

Webcast link: [click here](#)

Participants can use the audio-only link above to register and obtain dial-in instructions to listen to the presentation via phone and ask questions during the Q&A session, or participants can use the webcast link to register and listen and watch the slide presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company’s website at [www.nanobiotix.com](http://www.nanobiotix.com). It is recommended to join 10 minutes prior to the event start. Participants are invited to email their questions in advance to [investors@nanobiotix.com](mailto:investors@nanobiotix.com).

### Next Annual General Meeting of the Company

The Company announced that its next Annual General Meeting (“AGM”) will be held on May 28, 2024, at its headquarters, 60 rue de Wattignies, 75012 Paris, France. The notice of meeting of this AGM has been published in the French legal bulletin and includes the agenda, the proposed resolutions as well as instructions to participate and vote in this AGM. All documentation regarding this AGM is available on the Company’s website.

### About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

### Contacts

---

#### *Nanobiotix*

---

#### **Communications Department**

*Brandon Owens*  
 VP, Communications  
 +1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

---

#### **Investor Relations Department**

*Craig West*  
 SVP, Investor Relations  
 +1 (617) 583-0211  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

---

#### *Media Relations*

---

#### **FR –Ulysse Communication**

Laurent Wormser  
 + 33 (0)6 13 12 04 04  
[lwormser@ulyse-communication.com](mailto:lwormser@ulyse-communication.com)

---

#### **Global –LifeSci Advisors**

Kevin Gardner  
 +1 (617) 283-2856  
[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)

### Attachment

- 2024-05-15 -- NBTX -- 1Q24 STD -- FINAL.pdf (<https://ml.globenewswire.com/Resource/Download/745b6f22-86ea-47f3-97d2-a60bba3cb908>)